AIMEDBIO

PR

Press Release

AimedBio Signs Co-Development Agreement with GeneQuantum
2023.06.30

- AimedBio and GeneQuantum have signed a co-development agreement to jointly develop up to five ADC (antibody-drug conjugate) candidates.

  • - The agreement builds on their existing partnership and aims to accelerate the discovery and development of multiple next-generation ADC programs.

Link: http://www.biospectator.com/view/news_view.php?varAtcId=19343 

LIST